United States soft tissue sarcoma market
is poised to witness significant growth until 2025 owing to the rise in pool of
patients suffering from different types of cancers including soft tissue
sarcoma. The government’s focus on providing best healthcare facilities and
increasing funding for the development of new drugs are some key factors
supporting the growth of soft tissue sarcoma market. Moreover, rising awareness
among people about chronic diseases such as soft tissue sarcoma is also acting
as a major factor behind the market growth. Moreover, the rise
in quality patient care and patent expiry of branded drugs are some other
factors which are anticipated to drive the soft tissue sarcoma market growth in
the United States during the next five years.
Soft
tissue sarcoma is a rare type of cancer which
can develop in soft tissues such as fat, muscle, nerves, fibrous tissues, blood
vessels, or deep skin tissues. There are around 50 different types of soft
tissue sarcoma and most of them are difficult to diagnose as they may be
mistaken for many other types of growths. The most common types occur in the
arms and legs, and in the abdomen.
United States soft tissue sarcoma market
can be segmented based on treatment, disease type, end user
and region. Based on treatment, the market is divided into targeted therapy,
chemotherapy, anti-angiogenesis drug and radiation therapy. Here, the chemotherapy
treatment is the most common one and is expected to dominate the market during
the forecast period. A combination of various anti-cancer drugs is used during
this treatment and the success rate is comparatively high.
Major companies operating in United
States soft tissue sarcoma market include GlaxoSmithKline LLC, Eli Lilly and
Company, Pfizer, Inc., Bristol-Myers Squibb Co, Hoffmann-La Roche Inc, Johnson
& Johnson Services, Inc., Teva Pharmaceuticals USA Inc, Celgene
Corporation, BioHorizons, Zimmer Biomet Holdings Inc and MiMedx Group Inc, among
others. With the use of latest technologies, manufacturers are focusing on
launching new drugs which can be more effective for treatment of soft tissue
sarcoma.
Years
considered for this report:
Historical Years: 2015-2018
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2021–2025
Objective of the Study:
- To analyze and forecast the market size of United States soft
tissue sarcoma market.
- To forecast United States soft tissue sarcoma market based on treatment, disease type, end user,
company and regional distribution.
- To identify drivers and challenges for United States soft tissue
sarcoma market.
- To examine competitive developments such as expansions, new product
launches, mergers & acquisitions etc. in United States soft tissue
sarcoma market.
- To identify and analyze the profile of leading players operating in
the United States soft tissue sarcoma market.
Click here to download the sample
TechSci Research performed both primary as well as
exhaustive secondary research for this study. Initially, TechSci Research
sourced a list of soft tissue sarcoma treatment companies across United States.
Subsequently, TechSci Research conducted primary research surveys with the
identified companies. While interviewing, the respondents were also enquired
about their competitors. Through this technique, TechSci Research could include
the companies which could not be identified due to the limitations of secondary
research.
TechSci
Research calculated United States soft tissue sarcoma market size using a
bottom-up approach, where data for various end user industries and its
application across various product types were recorded and forecast for the
future years. TechSci Research sourced these values from the industry experts
and company representatives and externally validated through analyzing
historical data of these product types and applications for getting an
appropriate, overall market size. Various secondary sources such as company
websites, news articles, press releases, company annual reports, investor
presentations and financial reports were also used by TechSci Research.
Key Target
Audience:
- Soft tissue sarcoma drug manufacturers,
companies/partners, hospital/oncology centers and other stakeholders
- Government bodies such as regulating
authorities and policy makers
- Organizations, industry associations, forums
and alliances related to soft tissue sarcoma
- Market research and consulting firms
The study is useful in providing answers to several critical
questions that are important for the industry stakeholders such as soft tissue
sarcoma drug manufacturing companies, end users etc., besides allowing them in
strategizing investments and capitalizing on market opportunities.
Report Scope:
In this report, United States soft tissue sarcoma market has
been segmented into following categories, in addition to the industry trends
which have also been detailed below:
- United States Soft Tissue Sarcoma Market, By Treatment:
- Targeted Therapy
- Chemotherapy
- Anti-Angiogenesis
Drug
- Radiation Therapy
- United States Soft Tissue Sarcoma Market, By Disease Type:
- Local Sarcoma
- Regional Sarcoma
- Metastatic
Sarcoma
- United States Soft Tissue Sarcoma Market, By End User:
- Hospitals
- Oncology Center
- Long Term Care Center
- United
States Soft Tissue Sarcoma Market, By Region:
- North-East
- Mid-West
- South
- West
Competitive Landscape
Company Profiles: Detailed analysis of the major
companies present in United States soft tissue sarcoma market.
Available Customizations:
With the given market data, TechSci Research offers
customizations according to a company’s specific needs. The following
customization options are available for the report:
Company Information
- Detailed analysis and profiling of
additional market players (up to five).
Profit Margin Analysis
- Profit margin analysis in case of direct
and indirect sales channel.
It is an upcoming report to
be released soon. If you wish an early delivery of this report or want to
confirm the date of release, please contact us at [email protected]